Literature DB >> 32371182

Prediction of pathological complete response in breast cancer patients during neoadjuvant chemotherapy: Is shear wave elastography a useful tool in clinical routine?

Anna Marie Maier1, Jörg Heil1, Aba Harcos1, Hans-Peter Sinn2, Geraldine Rauch3, Lorenz Uhlmann4, Christina Gomez1, Anne Stieber5, Annika Funk1, Richard G Barr6, André Hennigs1, Fabian Riedel1, Benedikt Schäfgen1, Sarah Hug1, Frederik Marmé7, Christof Sohn1, Michael Golatta8.   

Abstract

OBJECTIVE: To compare the validity of Shear Wave Elastography (SWE) for the preoperative assessment of pathological complete response (pCR) to standard clinical assessment in breast cancer patients undergoing neoadjuvant chemotherapy (NACT).
MATERIALS AND METHODS: This prospective, consecutive clinical trial was conducted under routine clinical practice. Analysis included 134 patients. SWE served as index test, final pathology from surgical specimen as reference standard. PCR (ypT0) was defined as primary endpoint. Elasticity changes were compared for the pCR- vs. non-pCR group. To determine the validity of shear wave velocity (Vs), ROC analyses and diagnostic accuracy parameters were calculated and compared to the final standard clinical assessment by physical examination, mammography and B-mode ultrasound (ycT + vs. ycT0).
RESULTS: Vs was significantly reduced in pCR and non-pCR groups during NACT (pCR: ΔVs(abs) = 3.90 m/s, p < 0.001; non-pCR: ΔVs(abs) = 3.10 m/s, p < 0.001). The pCR-group showed significant lower Vs for all control visits (t1,2,END: p < 0.001). ROC analysis of Vs yielded moderate AUCs for the total population (t0: 0.613, t1: 0.745, t2: 0.685, tEND: 0.718). Compared to standard clinical assessment, Vs(tEND) (cut-off: ≤3.35 m/s) was superior in sensitivity (79.6 % vs. 54.5 %), NPV (86.4 % vs. 77.5 %), FNR (20.4 % vs. 45.5 %), inferior in specificity (58.6 % vs. 77.5 %), PPV (46.3 % vs. 54.5 %), FPR (41.4 % vs. 22.5 %).
CONCLUSION: SWE measures significant differences in tumour elasticity changes in pCR vs. non-pCR cases. SWE shows improved sensitivity compared to standard clinical assessment, high NPV and low FNR, but failed in specificity in order to predict pCR under routine conditions.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  2D shear wave imaging; Breast neoplasms; Elasticity imaging techniques; Neoadjuvant therapy

Mesh:

Year:  2020        PMID: 32371182     DOI: 10.1016/j.ejrad.2020.109025

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  Usefulness of new shear wave elastography in early predicting the efficacy of neoadjuvant chemotherapy for patients with breast cancer: where and when to measure is optimal?

Authors:  Jiong-Hui Gu; Chang He; Qi-Yu Zhao; Tian-An Jiang
Journal:  Breast Cancer       Date:  2022-01-17       Impact factor: 3.307

Review 2.  Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Xianshu Kong; Qian Zhang; Xuemei Wu; Tianning Zou; Jiajun Duan; Shujie Song; Jianyun Nie; Chu Tao; Mi Tang; Maohua Wang; Jieya Zou; Yu Xie; Zhenhui Li; Zhen Li
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

3.  Accuracy of ultrasound elastography for predicting breast cancer response to neoadjuvant chemotherapy: A systematic review and meta-analysis.

Authors:  Wei Chen; Li-Xiang Fang; Hai-Lan Chen; Jian-Hua Zheng
Journal:  World J Clin Cases       Date:  2022-04-16       Impact factor: 1.534

4.  Added value of systemic inflammation markers for monitoring response to neoadjuvant chemotherapy in breast cancer patients.

Authors:  Zi-Rui Ke; Wei Chen; Man-Xiu Li; Shun Wu; Li-Ting Jin; Tie-Jun Wang
Journal:  World J Clin Cases       Date:  2022-04-16       Impact factor: 1.534

5.  A Novel Model Incorporating Tumor Stiffness, Blood Flow Characteristics, and Ki-67 Expression to Predict Responses After Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Jing Zhang; Song Gao; Qiaojin Zheng; Ye Kang; Jianyi Li; Shuo Zhang; Cong Shang; Xueying Tan; Weidong Ren; Yan Ma
Journal:  Front Oncol       Date:  2020-12-08       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.